Gryaznov S, Skorski T, Cucco C, Nieborowska-Skorska M, Chiu C Y, Lloyd D, Chen J K, Koziolkiewicz M, Calabretta B
Lynx Therapeutics, Inc., Hayward, CA 94545, USA.
Nucleic Acids Res. 1996 Apr 15;24(8):1508-14. doi: 10.1093/nar/24.8.1508.
Uniformly modified oligonucleotide N3'-->P5' phosphoramidates, where every 3'-oxygen is replaced by a 3'-amino group, were synthesized. These compounds have very high affinity to single-stranded RNAs and thus have potential utility as antisense agents. As was shown in this study, the oligonucleotide phosphoramidates are resistant to digestion with snake venom phosphodiesterase, to nuclease activity in a HeLa cell nuclear extract, or to nuclease activity in 50% human plasma, where no significant hydrolysis was observed after 8 h. These compounds were used in various in vitro cellular systems as antisense compounds addressed to different targeted regions of c-myb, c-myc and bcr-abl mRNAs. C-myb antisense phosphoramidates at 5 microM caused sequence and dose-dependent inhibition of HL-60 cell proliferation and a 75% reduction in c-myb protein and RNA levels, as determined by Western blot and RT-PCR analysis. Analogous results were observed for anti-c-myc phosphoramidates, where a complete cytostatic effect for HL-60 cells was observed at 1 microM concentration for fully complementary, but not for mismatched compounds, which were indistinguishable from untreated controls. This was correlated with a 93% reduction in c-myc protein level. Moreover, colony formation by the primary CML cells was also inhibited 75-95% and up to 99% by anti-c-myc and anti-bcr-abl phosphoramidate oligonucleotides, respectively, in a sequence- and dose-dependent manner within a 0.5 nM-5 microM dose range. At these concentrations the colony-forming ability of normal bone marrow cells was not affected. The presented in vitro data indicate that oligonucleotide N3'-->P5' phosphoramidates could be used as specific and efficient antisense agents.
合成了均匀修饰的寡核苷酸N3'→P5'氨基磷酸酯,其中每个3'-氧被3'-氨基取代。这些化合物对单链RNA具有非常高的亲和力,因此具有作为反义剂的潜在用途。如本研究所示,寡核苷酸氨基磷酸酯对蛇毒磷酸二酯酶消化、HeLa细胞核提取物中的核酸酶活性或50%人血浆中的核酸酶活性具有抗性,在8小时后未观察到明显的水解。这些化合物在各种体外细胞系统中用作针对c-myb、c-myc和bcr-abl mRNA不同靶向区域的反义化合物。5μM的c-myb反义氨基磷酸酯导致HL-60细胞增殖的序列和剂量依赖性抑制,通过蛋白质免疫印迹和逆转录-聚合酶链反应分析确定,c-myb蛋白和RNA水平降低了75%。对于抗c-myc氨基磷酸酯也观察到了类似的结果,在1μM浓度下,对于完全互补的化合物,HL-60细胞观察到完全的细胞生长抑制作用,但对于错配的化合物则没有,错配化合物与未处理的对照无明显差异。这与c-myc蛋白水平降低93%相关。此外,在0.5 nM-5μM剂量范围内,抗c-myc和抗bcr-abl氨基磷酸酯寡核苷酸分别以序列和剂量依赖性方式抑制原代慢性粒细胞白血病细胞的集落形成75%-95%和高达99%。在这些浓度下,正常骨髓细胞的集落形成能力不受影响。所呈现的体外数据表明,寡核苷酸N3'→P5'氨基磷酸酯可作为特异性和高效的反义剂。